Amicus Therapeutics, Inc. (FOLD)
USD 7.5
(-6.31%)
USD 7.5
(-6.31%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 617.7 Million USD | 2.76% |
| 2022 | 601.12 Million USD | 0.56% |
| 2021 | 597.77 Million USD | -0.39% |
| 2020 | 600.14 Million USD | 60.56% |
| 2019 | 373.78 Million USD | -16.39% |
| 2018 | 447.03 Million USD | 63.05% |
| 2017 | 274.17 Million USD | -59.48% |
| 2016 | 676.69 Million USD | 20.72% |
| 2015 | 560.55 Million USD | 538.52% |
| 2014 | 87.78 Million USD | 7.31% |
| 2013 | 81.81 Million USD | 100.19% |
| 2012 | 40.86 Million USD | 1.65% |
| 2011 | 40.2 Million USD | -15.57% |
| 2010 | 47.61 Million USD | 251.76% |
| 2009 | 13.53 Million USD | -76.55% |
| 2008 | 57.73 Million USD | -9.51% |
| 2007 | 63.8 Million USD | -53.49% |
| 2006 | 137.16 Million USD | 112.65% |
| 2005 | 64.49 Million USD | 0.0% |
| 2003 | 5.77 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 616.96 Million USD | 4.38% |
| 2024 Q1 | 591.09 Million USD | -4.31% |
| 2023 Q4 | 617.7 Million USD | -2.08% |
| 2023 Q2 | 618.51 Million USD | 3.44% |
| 2023 Q1 | 597.94 Million USD | -0.53% |
| 2023 FY | 617.7 Million USD | 2.76% |
| 2023 Q3 | 630.84 Million USD | 1.99% |
| 2022 Q1 | 588.32 Million USD | -1.58% |
| 2022 Q2 | 627.16 Million USD | 6.6% |
| 2022 Q3 | 626.96 Million USD | -0.03% |
| 2022 Q4 | 601.12 Million USD | -4.12% |
| 2022 FY | 601.12 Million USD | 0.56% |
| 2021 FY | 597.77 Million USD | -0.39% |
| 2021 Q2 | 572.98 Million USD | 2.48% |
| 2021 Q3 | 580.04 Million USD | 1.23% |
| 2021 Q1 | 559.13 Million USD | -6.83% |
| 2021 Q4 | 597.77 Million USD | 3.06% |
| 2020 Q3 | 580.27 Million USD | 70.42% |
| 2020 Q1 | 335.75 Million USD | -10.17% |
| 2020 Q2 | 340.49 Million USD | 1.41% |
| 2020 FY | 600.14 Million USD | 60.56% |
| 2020 Q4 | 600.14 Million USD | 3.42% |
| 2019 Q4 | 373.78 Million USD | 11.9% |
| 2019 FY | 373.78 Million USD | -16.39% |
| 2019 Q1 | 313.03 Million USD | -29.98% |
| 2019 Q2 | 317.97 Million USD | 1.58% |
| 2019 Q3 | 334.02 Million USD | 5.05% |
| 2018 Q1 | 348.38 Million USD | 27.07% |
| 2018 Q3 | 427.63 Million USD | 61.99% |
| 2018 Q4 | 447.03 Million USD | 4.54% |
| 2018 FY | 447.03 Million USD | 63.05% |
| 2018 Q2 | 263.99 Million USD | -24.22% |
| 2017 Q2 | 672.07 Million USD | -1.54% |
| 2017 FY | 274.17 Million USD | -59.48% |
| 2017 Q4 | 274.17 Million USD | 1.13% |
| 2017 Q3 | 271.09 Million USD | -59.66% |
| 2017 Q1 | 682.6 Million USD | 0.87% |
| 2016 Q1 | 551.27 Million USD | -1.65% |
| 2016 FY | 676.69 Million USD | 20.72% |
| 2016 Q4 | 676.69 Million USD | 16.35% |
| 2016 Q3 | 581.62 Million USD | 0.32% |
| 2016 Q2 | 579.76 Million USD | 5.17% |
| 2015 Q3 | 607.93 Million USD | 710.46% |
| 2015 FY | 560.55 Million USD | 538.52% |
| 2015 Q1 | 88.6 Million USD | 0.93% |
| 2015 Q2 | 75.01 Million USD | -15.34% |
| 2015 Q4 | 560.55 Million USD | -7.79% |
| 2014 Q1 | 81.27 Million USD | -0.66% |
| 2014 FY | 87.78 Million USD | 7.31% |
| 2014 Q2 | 81.68 Million USD | 0.51% |
| 2014 Q3 | 82.21 Million USD | 0.64% |
| 2014 Q4 | 87.78 Million USD | 6.79% |
| 2013 Q4 | 81.81 Million USD | 91.97% |
| 2013 Q2 | 42.77 Million USD | 7.26% |
| 2013 Q1 | 39.87 Million USD | -2.42% |
| 2013 FY | 81.81 Million USD | 100.19% |
| 2013 Q3 | 42.61 Million USD | -0.37% |
| 2012 Q4 | 40.86 Million USD | -1.41% |
| 2012 Q3 | 41.45 Million USD | 7.86% |
| 2012 Q1 | 40.02 Million USD | -0.44% |
| 2012 FY | 40.86 Million USD | 1.65% |
| 2012 Q2 | 38.43 Million USD | -3.98% |
| 2011 Q4 | 40.2 Million USD | -4.46% |
| 2011 Q1 | 49.49 Million USD | 3.93% |
| 2011 FY | 40.2 Million USD | -15.57% |
| 2011 Q3 | 42.07 Million USD | -7.89% |
| 2011 Q2 | 45.68 Million USD | -7.7% |
| 2010 Q3 | 13.27 Million USD | 26.1% |
| 2010 FY | 47.61 Million USD | 251.76% |
| 2010 Q4 | 47.61 Million USD | 258.81% |
| 2010 Q2 | 10.52 Million USD | -24.52% |
| 2010 Q1 | 13.94 Million USD | 3.0% |
| 2009 Q3 | 61.73 Million USD | 2.82% |
| 2009 Q2 | 60.03 Million USD | 6.98% |
| 2009 Q4 | 13.53 Million USD | -78.07% |
| 2009 FY | 13.53 Million USD | -76.55% |
| 2009 Q1 | 56.11 Million USD | -2.79% |
| 2008 Q3 | 60.15 Million USD | -2.06% |
| 2008 Q1 | 61.84 Million USD | -3.06% |
| 2008 FY | 57.73 Million USD | -9.51% |
| 2008 Q4 | 57.73 Million USD | -4.02% |
| 2008 Q2 | 61.41 Million USD | -0.7% |
| 2007 Q3 | 11.14 Million USD | 24.96% |
| 2007 Q1 | 159.33 Million USD | 16.16% |
| 2007 Q2 | 8.91 Million USD | -94.4% |
| 2007 Q4 | 63.8 Million USD | 472.51% |
| 2007 FY | 63.8 Million USD | -53.49% |
| 2006 Q4 | 137.16 Million USD | 0.0% |
| 2006 FY | 137.16 Million USD | 112.65% |
| 2005 Q4 | 64.49 Million USD | 0.0% |
| 2005 FY | 64.49 Million USD | 0.0% |
| 2003 FY | 5.77 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | -83.964% |
| Alkermes plc | 933.53 Million USD | 33.832% |
| Agenus Inc. | 462.29 Million USD | -33.617% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 84.75% |
| Aptorum Group Limited | 5.25 Million USD | -11650.747% |
| Ardelyx, Inc. | 130.76 Million USD | -372.386% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | -29.122% |
| Bicycle Therapeutics plc | 224.41 Million USD | -175.255% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -374.392% |
| ChromaDex Corporation | 26.5 Million USD | -2230.263% |
| Chimerix, Inc. | 19.74 Million USD | -3028.417% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1655.988% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -751.222% |
| CRISPR Therapeutics AG | 346.76 Million USD | -78.132% |
| Precision BioSciences, Inc. | 140.92 Million USD | -338.338% |
| Dyadic International, Inc. | 2.34 Million USD | -26290.35% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -3698.229% |
| Fortress Biotech, Inc. | 165.93 Million USD | -272.249% |
| Lantern Pharma Inc. | 2.73 Million USD | -22446.631% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -764.166% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -17405.076% |
| Incyte Corporation | 1.59 Billion USD | 61.206% |
| IO Biotech, Inc. | 17.55 Million USD | -3418.489% |
| Jaguar Health, Inc. | 45.86 Million USD | -1246.762% |
| Novavax, Inc. | 2.57 Billion USD | 75.986% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -1613.09% |
| Opthea Limited | 264.6 Million USD | -133.448% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -372.588% |
| ContextLogic Inc. | 206 Million USD | -199.857% |
| MiMedx Group, Inc. | 96.33 Million USD | -541.239% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -1186.298% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -17404.273% |
| NextCure, Inc. | 14.99 Million USD | -4018.864% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -15182.187% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -9151.251% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -1221.607% |
| Vaxcyte, Inc. | 167.44 Million USD | -268.892% |
| PDS Biotechnology Corporation | 33.25 Million USD | -1757.252% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -162.614% |
| Pharming Group N.V. | 244.07 Million USD | -153.082% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -5081.228% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -383.372% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -9248.871% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -9248.871% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -649.343% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -9198.6% |
| Acelyrin, Inc. | 86.35 Million USD | -615.327% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -47443.604% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -4195.89% |
| Summit Therapeutics Inc. | 125.25 Million USD | -393.151% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -6416.573% |
| Senti Biosciences, Inc. | 52.57 Million USD | -1074.994% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -798.129% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -307.694% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -31480.061% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -46150.573% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -172.319% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -6494.491% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -171.585% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | -24.913% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -5559.758% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -2145.306% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -5003.027% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | -26.943% |
| Immix Biopharma, Inc. | 3.72 Million USD | -16497.045% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -1533.624% |
| MEI Pharma, Inc. | 8.35 Million USD | -7293.25% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -2028.92% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | -77.716% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -323.466% |
| Fortress Biotech, Inc. | 165.93 Million USD | -272.249% |
| Precigen, Inc. | 41.64 Million USD | -1383.301% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -1137.144% |
| AlloVir, Inc. | 45.01 Million USD | -1272.223% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -373.93% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -348.263% |
| ImmuCell Corporation | 18.81 Million USD | -3183.046% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -2088.429% |
| Onconetix, Inc. | 23.18 Million USD | -2564.721% |
| PureTech Health plc | 125.58 Million USD | -391.871% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -6801.743% |
| Elevation Oncology, Inc. | 34.28 Million USD | -1701.838% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -25164.049% |
| Seer, Inc. | 39.36 Million USD | -1469.176% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -898.975% |
| Innoviva, Inc. | 568.55 Million USD | -8.645% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -2168.643% |
| ESSA Pharma Inc. | 3.49 Million USD | -17573.632% |
| GlycoMimetics, Inc. | 6.9 Million USD | -8849.571% |
| GT Biopharma, Inc. | 6.63 Million USD | -9212.619% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | -133.634% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | -126.858% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -635.137% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -6219.89% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -2173.569% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -19049.085% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -737.374% |
| Aptose Biosciences Inc. | 15.8 Million USD | -3807.38% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -5495.322% |
| Soligenix, Inc. | 7.27 Million USD | -8390.916% |
| Century Therapeutics, Inc. | 175.94 Million USD | -251.087% |
| Kura Oncology, Inc. | 51.66 Million USD | -1095.668% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -409.314% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -14845.705% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -9239.576% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -144.541% |
| Autolus Therapeutics plc | 263.9 Million USD | -134.062% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -5793.017% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -595.137% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -1217.098% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | -75.059% |
| GRI Bio, Inc. | 2.69 Million USD | -22803.448% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -76199.092% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -1886.768% |
| IGM Biosciences, Inc. | 220.17 Million USD | -180.55% |
| INmune Bio, Inc. | 18.86 Million USD | -3174.87% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -140.841% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -2218.559% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -22623.096% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -18730.973% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -956.721% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -542.38% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -133.33% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 24.947% |
| Verastem, Inc. | 71.18 Million USD | -767.747% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -1156.113% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -1501.187% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -1162.376% |
| Histogen Inc. | 5.69 Million USD | -10742.654% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -13984.853% |
| Surrozen, Inc. | 8.14 Million USD | -7483.867% |
| Organovo Holdings, Inc. | 2.74 Million USD | -22378.384% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -196710.66% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -998.537% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -3640.952% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -1108.747% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -74603.673% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -387.438% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -5612.312% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -309.378% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -23590.996% |
| Apollomics, Inc. | 14.15 Million USD | -4264.488% |
| Amarin Corporation plc | 279.58 Million USD | -120.935% |
| Mesoblast Limited | 188.79 Million USD | -227.178% |
| Turnstone Biologics Corp. | 14.14 Million USD | -4266.031% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -241.674% |
| Synaptogenix, Inc. | 5.52 Million USD | -11071.163% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -9191.606% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -263.126% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -7118.559% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -35048.996% |
| Exelixis, Inc. | 678.44 Million USD | 8.953% |
| Better Therapeutics, Inc. | 23.84 Million USD | -2490.831% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -276.544% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | -3.954% |
| NLS Pharmaceutics AG | 10.68 Million USD | -5683.654% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -37945.08% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -1486.832% |
| Gritstone bio, Inc. | 125.91 Million USD | -390.558% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -4108.953% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -12038.952% |
| Avid Bioservices, Inc. | 275.66 Million USD | -124.076% |
| Insmed Incorporated | 1.66 Billion USD | 62.828% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -7928.387% |
| MediWound Ltd. | 27.18 Million USD | -2172.064% |
| OmniAb, Inc. | 87.4 Million USD | -606.757% |
| Alector, Inc. | 487.66 Million USD | -26.665% |
| Seres Therapeutics, Inc. | 403.45 Million USD | -53.104% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -3252.543% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -1509.741% |
| Zai Lab Limited | 240.17 Million USD | -157.188% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 1.96% |
| Aura Biosciences, Inc. | 29.22 Million USD | -2013.477% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -549.69% |
| Immunic, Inc. | 25.36 Million USD | -2334.981% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -792.175% |
| Veracyte, Inc. | 93.71 Million USD | -559.104% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -23506.542% |
| FibroGen, Inc. | 585.72 Million USD | -5.46% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -3453.506% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -94484.091% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -10822.298% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 91.932% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -7434.838% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -635.172% |
| TG Therapeutics, Inc. | 169.08 Million USD | -265.323% |
| Galecto, Inc. | 5.89 Million USD | -10376.696% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -7356.615% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 76.409% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -2043.175% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -4794.271% |
| XBiotech Inc. | 8.39 Million USD | -7256.27% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -4108.953% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -1061.538% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | -70.117% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -2197.671% |
| Theravance Biopharma, Inc. | 169 Million USD | -265.498% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 49.185% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | -23.436% |
| Vaxxinity, Inc. | 30.94 Million USD | -1896.206% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 36.482% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -10142.0% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 17.112% |
| NexImmune, Inc. | 5.08 Million USD | -12049.446% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -166220.942% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -19988.993% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 91.309% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -11884.913% |
| Scopus BioPharma Inc. | 7.45 Million USD | -8186.424% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -2249.228% |
| Ainos, Inc. | 7.39 Million USD | -8253.9% |
| Pluri Inc. | 34.11 Million USD | -1710.817% |
| Prothena Corporation plc | 135.01 Million USD | -357.502% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -154.092% |
| Celularity Inc. | 102.92 Million USD | -500.128% |
| Rallybio Corporation | 9.43 Million USD | -6446.27% |
| Cue Biopharma, Inc. | 24.44 Million USD | -2426.922% |
| MeiraGTx Holdings plc | 319.99 Million USD | -93.039% |
| Omeros Corporation | 403.25 Million USD | -53.181% |
| Humacyte, Inc. | 114.67 Million USD | -438.649% |
| Immunocore Holdings plc | 228.15 Million USD | -170.736% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -12570.892% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -704.934% |
| Blueprint Medicines Corporation | 918.64 Million USD | 32.759% |
| CalciMedica, Inc. | 4.02 Million USD | -15235.303% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -3439.457% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -300.736% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -619.794% |
| Sana Biotechnology, Inc. | 277.79 Million USD | -122.362% |
| Pulmatrix, Inc. | 15.96 Million USD | -3769.611% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -3816.224% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -2410.388% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -146.286% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -1116.292% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 48.977% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -1843.511% |
| Nutriband Inc. | 1.07 Million USD | -57152.305% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -5709.329% |
| Vor Biopharma Inc. | 59.1 Million USD | -945.117% |
| Roivant Sciences Ltd. | 773.95 Million USD | 20.188% |
| Evogene Ltd. | 17.99 Million USD | -3333.608% |
| ProKidney Corp. | 29.21 Million USD | -2014.273% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -758.175% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -87519.985% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 67.298% |
| CorMedix Inc. | 11.91 Million USD | -5083.172% |
| BioLineRx Ltd. | 50.7 Million USD | -1118.307% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -313.295% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -598.439% |
| Atai Life Sciences N.V. | 49.16 Million USD | -1156.47% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -1882.858% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -3338.96% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -395.608% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -10825.115% |
| MediciNova, Inc. | 3.89 Million USD | -15772.995% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -3279.321% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -40964.298% |
| GeoVax Labs, Inc. | 3.51 Million USD | -17449.059% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -55.492% |
| Biomea Fusion, Inc. | 30.69 Million USD | -1912.727% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 77.305% |
| Mereo BioPharma Group plc | 15.96 Million USD | -3769.853% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -1879.763% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -952.597% |
| Absci Corporation | 58.3 Million USD | -959.457% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -3142.892% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -1826.599% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -737.113% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -606.087% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -1729.156% |
| Allakos Inc. | 74.79 Million USD | -725.887% |
| Imunon, Inc. | 8.53 Million USD | -7141.208% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -2645.238% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -438.015% |
| BioAtla, Inc. | 48.98 Million USD | -1160.985% |
| NLS Pharmaceutics AG | 10.68 Million USD | -5683.654% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -22127.636% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -372.961% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -4245.452% |
| XOMA Corporation | 145.58 Million USD | -324.307% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -1734.861% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -798.364% |
| aTyr Pharma, Inc. | 31.59 Million USD | -1854.951% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -899.152% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -1273.748% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -1176.199% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -21422.857% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -7471.766% |
| Akari Therapeutics, Plc | 4.58 Million USD | -13375.262% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -3383.344% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 62.551% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -152832.351% |
| UroGen Pharma Ltd. | 243.52 Million USD | -153.654% |
| Sutro Biopharma, Inc. | 321.08 Million USD | -92.38% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -22268.026% |
| Orgenesis Inc. | 35.53 Million USD | -1638.303% |
| Entera Bio Ltd. | 1.37 Million USD | -44693.764% |
| GH Research PLC | 6.7 Million USD | -9118.117% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -8983.912% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -3181.132% |
| Xencor, Inc. | 283.55 Million USD | -117.84% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -20588.99% |
| Replimune Group, Inc. | 113.21 Million USD | -445.609% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -16340.922% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -496.644% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -152832.351% |
| Portage Biotech Inc. | 4.45 Million USD | -13781.034% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -40964.298% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -2579.852% |
| OncoCyte Corporation | 49.29 Million USD | -1153.004% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -14831.958% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -77356.852% |
| Purple Biotech Ltd. | 10 Million USD | -6073.973% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -10575.873% |
| scPharmaceuticals Inc. | 57.26 Million USD | -978.755% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -4886.317% |
| HilleVax, Inc. | 78.9 Million USD | -682.808% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -12131.802% |
| Tharimmune, Inc. | 1.81 Million USD | -33932.526% |
| Genprex, Inc. | 3.25 Million USD | -18881.761% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -2177.761% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -11697.288% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -299757.282% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -172179.862% |
| OKYO Pharma Limited | 7.42 Million USD | -8223.93% |
| Savara Inc. | 37.19 Million USD | -1560.857% |
| Curis, Inc. | 57.61 Million USD | -972.183% |
| Daré Bioscience, Inc. | 26.32 Million USD | -2246.029% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -1475.789% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -42677.424% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -2867.03% |
| BeiGene, Ltd. | 2.23 Billion USD | 72.347% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -2801.418% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | -135.409% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -2803.572% |
| Erasca, Inc. | 78.61 Million USD | -685.776% |
| bluebird bio, Inc. | 424.62 Million USD | -45.471% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -94169.991% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 67.318% |
| DBV Technologies S.A. | 42.8 Million USD | -1343.238% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -94169.991% |
| Moderna, Inc. | 4.57 Billion USD | 86.489% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -8730.679% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -37201.087% |
| Molecular Templates, Inc. | 31.17 Million USD | -1881.669% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -3518.664% |
| Travere Therapeutics, Inc. | 588.1 Million USD | -5.034% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -396.129% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -2151.361% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -1594.388% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -1010.283% |
| MacroGenics, Inc. | 154.2 Million USD | -300.569% |
| RenovoRx, Inc. | 4.46 Million USD | -13731.303% |
| Adicet Bio, Inc. | 37.12 Million USD | -1564.079% |
| Prime Medicine, Inc. | 60.78 Million USD | -916.298% |
| Aditxt, Inc. | 28.53 Million USD | -2064.992% |
| Adagene Inc. | 45.16 Million USD | -1267.534% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -341738.728% |
| Quantum-Si incorporated | 26.63 Million USD | -2219.5% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 11.448% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -20202.994% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -437.318% |
| SciSparc Ltd. | 1.59 Million USD | -38627.649% |
| Vericel Corporation | 127.7 Million USD | -383.698% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -11000.05% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -623.664% |
| Generation Bio Co. | 171.63 Million USD | -259.906% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -5248.104% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -1376.67% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -144.444% |
| Invivyd, Inc. | 51.71 Million USD | -1094.489% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -571.587% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -9395.498% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -718.197% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -60400.098% |
| 2seventy bio, Inc. | 310.12 Million USD | -99.179% |
| ADMA Biologics, Inc. | 193.97 Million USD | -218.445% |
| Clene Inc. | 38.95 Million USD | -1485.854% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -1609.541% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | -140.375% |
| GeoVax Labs, Inc. | 3.51 Million USD | -17449.059% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -224.659% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -4971.619% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -211.466% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -4965.323% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -1183.918% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -1068.99% |
| Vir Biotechnology, Inc. | 369.85 Million USD | -67.013% |
| Evaxion Biotech A/S | 17.61 Million USD | -3406.211% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -283.838% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -303.239% |
| Trevena, Inc. | 48.26 Million USD | -1179.901% |
| Surrozen, Inc. | 8.14 Million USD | -7483.867% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -2760.412% |
| Cingulate Inc. | 10.36 Million USD | -5861.915% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -22362.036% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -1556.404% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -17122.991% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -4597.384% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | -94.736% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -2385.838% |
| Clearmind Medicine Inc. | 3.61 Million USD | -17010.932% |
| Kronos Bio, Inc. | 54.2 Million USD | -1039.658% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -1213.067% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -2614.03% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -2977.605% |
| Statera Biopharma, Inc. | 22.67 Million USD | -2623.997% |
| ImmunityBio, Inc. | 1.09 Billion USD | 43.35% |
| Korro Bio, Inc. | 51.75 Million USD | -1093.589% |
| Kineta, Inc. | 7.22 Million USD | -8453.115% |
| BioVie Inc. | 9.7 Million USD | -6266.705% |
| Codexis, Inc. | 49.94 Million USD | -1136.748% |
| Celularity Inc. | 102.92 Million USD | -500.128% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -541.792% |
| Celcuity Inc. | 51.45 Million USD | -1100.593% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -178844.593% |
| Cibus, Inc. | 206.11 Million USD | -199.687% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -1354.281% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -2245.214% |
| IN8bio, Inc. | 8.77 Million USD | -6941.792% |
| Kodiak Sciences Inc. | 213.59 Million USD | -189.2% |
| Annexon, Inc. | 47.11 Million USD | -1210.977% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -589.858% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -540.96% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -4412.426% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 76.273% |
| Eyenovia, Inc. | 19.78 Million USD | -3022.837% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -248.817% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -7942.0% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -2463.202% |
| Arcellx, Inc. | 339.75 Million USD | -81.811% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -5091.679% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -151.57% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -6359.333% |
| Moolec Science SA | 13.94 Million USD | -4329.475% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -1331.466% |
| Geron Corporation | 146.12 Million USD | -322.719% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -1122.406% |
| Royalty Pharma plc | 6.29 Billion USD | 90.191% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -1452.962% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -209714.338% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -25007.122% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -226.559% |
| Humacyte, Inc. | 114.67 Million USD | -438.649% |
| Structure Therapeutics Inc. | 29.05 Million USD | -2026.281% |
| 89bio, Inc. | 59.96 Million USD | -930.145% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -2234.225% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -51547.659% |
| Genelux Corporation | 8.42 Million USD | -7236.176% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -8909.714% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -353.133% |
| Notable Labs, Ltd. | 4.42 Million USD | -13853.151% |
| Liquidia Corporation | 73.13 Million USD | -744.576% |
| Mustang Bio, Inc. | 17.61 Million USD | -3405.908% |
| Immunovant, Inc. | 48.95 Million USD | -1161.783% |
| Quantum-Si incorporated | 26.63 Million USD | -2219.5% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -1509.322% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -19806.735% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -736.309% |
| Acasti Pharma Inc. | 11.55 Million USD | -5244.865% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -2632.278% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -22623.096% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -1575.044% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -45224.843% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -10032.972% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -2387.24% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -2564.363% |
| PepGen Inc. | 34.63 Million USD | -1683.679% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -4986.512% |
| United Therapeutics Corporation | 1.18 Billion USD | 47.749% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -8744.588% |
| Solid Biosciences Inc. | 38.45 Million USD | -1506.183% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -7118.559% |
| Immuneering Corporation | 12 Million USD | -5043.969% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -196710.66% |
| Silo Pharma, Inc. | 1.56 Million USD | -39262.634% |
| Belite Bio, Inc | 4.21 Million USD | -14568.867% |
| XOMA Corporation | 145.58 Million USD | -324.307% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -25340.939% |
| Bionomics Limited | 10.15 Million USD | -5980.549% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -2774.254% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -2595.876% |
| uniQure N.V. | 624.01 Million USD | 1.012% |
| Cassava Sciences, Inc. | 14.19 Million USD | -4251.574% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -341738.728% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -262.964% |
| Forte Biosciences, Inc. | 3.66 Million USD | -16749.591% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -236947.697% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -9055.269% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -7942.0% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -3453.506% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -5745.061% |
| Altimmune, Inc. | 16.54 Million USD | -3634.393% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -2595.876% |
| Compugen Ltd. | 55.77 Million USD | -1007.496% |
| Peak Bio, Inc. | 20.75 Million USD | -2876.414% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -459.197% |
| Benitec Biopharma Inc. | 4.96 Million USD | -12348.73% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -291.342% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -721.702% |
| Zura Bio Limited | 21.29 Million USD | -2801.118% |
| PolyPid Ltd. | 17.46 Million USD | -3436.215% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -449.565% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -721.702% |
| Instil Bio, Inc. | 99.8 Million USD | -518.938% |
| argenx SE | 444.95 Million USD | -38.826% |
| Immunome, Inc. | 28.65 Million USD | -2055.44% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -7309.212% |
| Verona Pharma plc | 58.84 Million USD | -949.788% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -4167.989% |
| Shattuck Labs, Inc. | 14.85 Million USD | -4057.117% |
| CervoMed Inc. | 2.59 Million USD | -23696.849% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -12573.492% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -4750.079% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -5763.37% |
| Moolec Science SA | 13.94 Million USD | -4329.475% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -26258.223% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -1011.076% |
| AnaptysBio, Inc. | 364.28 Million USD | -69.566% |
| Design Therapeutics, Inc. | 11.95 Million USD | -5066.494% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -4769.962% |
| NeurAxis, Inc. | 1.91 Million USD | -32194.317% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -1486.791% |
| Lumos Pharma, Inc. | 13.33 Million USD | -4532.911% |
| Achilles Therapeutics plc | 19.08 Million USD | -3136.266% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -4167.989% |
| 180 Life Sciences Corp. | 5.38 Million USD | -11366.16% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -2518.731% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -2614.03% |
| Nutriband Inc. | 1.07 Million USD | -57152.305% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -1918.779% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -4156.812% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | -53.936% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -1802.214% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -4633.707% |
| Palisade Bio, Inc. | 2.73 Million USD | -22452.245% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -11659.109% |
| Beam Therapeutics Inc. | 478.38 Million USD | -29.123% |
| Neurogene Inc. | 36.54 Million USD | -1590.076% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | -55.222% |
| AEON Biopharma, Inc. | 159.88 Million USD | -286.334% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -1196.34% |
| Sesen Bio, Inc. | 30.98 Million USD | -1893.629% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -2279.361% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -8025.341% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -215.578% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -221.626% |
| Athira Pharma, Inc. | 30.05 Million USD | -1955.115% |
| Vaccinex, Inc. | 5.94 Million USD | -10295.591% |
| HCW Biologics Inc. | 15.05 Million USD | -4003.829% |
| XOMA Corporation | 145.58 Million USD | -324.307% |
| Nektar Therapeutics | 267.04 Million USD | -131.311% |
| Arvinas, Inc. | 644.6 Million USD | 4.172% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -3383.344% |
| Merus N.V. | 102.15 Million USD | -504.699% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -322.074% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -549.397% |
| Rezolute, Inc. | 11.73 Million USD | -5164.241% |
| Clene Inc. | 38.95 Million USD | -1485.854% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -21593.838% |
| BeyondSpring Inc. | 48.26 Million USD | -1179.716% |
| Synlogic, Inc. | 32.89 Million USD | -1777.811% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -4127.099% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -37703.305% |
| Peak Bio, Inc. | 20.75 Million USD | -2876.414% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -873.394% |
| Krystal Biotech, Inc. | 39.71 Million USD | -1455.386% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | -64.003% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -520.38% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -142647.605% |
| MannKind Corporation | 721.36 Million USD | 14.37% |
| Ikena Oncology, Inc. | 22.33 Million USD | -2665.641% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -29511.985% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -502.111% |
| Gossamer Bio, Inc. | 249.14 Million USD | -147.928% |
| CohBar, Inc. | 1.03 Million USD | -59660.38% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -5678.894% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -3142.892% |
| Legend Biotech Corporation | 589.93 Million USD | -4.708% |
| Mural Oncology plc | 37.92 Million USD | -1528.628% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -365.715% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -26811.401% |
| Disc Medicine, Inc. | 22.87 Million USD | -2600.354% |
| Champions Oncology, Inc. | 28.03 Million USD | -2103.339% |
| REGENXBIO Inc. | 262.22 Million USD | -135.561% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -18287.653% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -4828.243% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -4498.892% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -2813.021% |
| Vaxart, Inc. | 34.02 Million USD | -1715.447% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -2929.565% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -2064.968% |
| Cellectis S.A. | 249.57 Million USD | -147.503% |
| Longeveron Inc. | 5.33 Million USD | -11474.03% |
| Repare Therapeutics Inc. | 41.81 Million USD | -1377.094% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 74.318% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -923.234% |
| Revolution Medicines, Inc. | 262.39 Million USD | -135.409% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -29216.849% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -7060.978% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -5134.353% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -4298.675% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -28617.155% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 88.005% |
| Denali Therapeutics Inc. | 122.96 Million USD | -402.351% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -11000.05% |
| Veru Inc. | 32.81 Million USD | -1782.521% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -8892.663% |
| Cingulate Inc. | 10.36 Million USD | -5861.915% |
| Passage Bio, Inc. | 39.26 Million USD | -1473.292% |
| Context Therapeutics Inc. | 4.19 Million USD | -14636.355% |
| Exicure, Inc. | 8.54 Million USD | -7125.477% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -1993.351% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -5790.769% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -2702.532% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -278.993% |
| Nuvalent, Inc. | 31.82 Million USD | -1841.068% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -9609.875% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -880.143% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -3331.7% |
| OmniAb, Inc. | 87.4 Million USD | -606.757% |
| Anew Medical, Inc. | 8.24 Million USD | -7394.796% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -1513.269% |
| Lipocine Inc. | 2.63 Million USD | -23372.382% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -2251.195% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -1436.124% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -2218.559% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -616.979% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -11336.882% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -646.5% |
| Ocugen, Inc. | 23.98 Million USD | -2475.599% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -1231.062% |
| Q32 Bio Inc. | 233.12 Million USD | -164.964% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -6713.435% |
| Alumis Inc. Common Stock | 53.5 Million USD | -1054.547% |
| Equillium, Inc. | 27.95 Million USD | -2109.486% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -198.998% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -10878.19% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -9971.893% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -292.628% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -789.643% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -6093.037% |
| Dominari Holdings Inc. | 4.63 Million USD | -13226.99% |
| Edesa Biotech, Inc. | 1.84 Million USD | -33441.138% |
| vTv Therapeutics Inc. | 29.56 Million USD | -1989.174% |
| Bio-Techne Corporation | 744.34 Million USD | 17.013% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -389.858% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | -79.328% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -1422.381% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -2033.184% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -568.803% |
| Nkarta, Inc. | 105.6 Million USD | -484.949% |
| BioCardia, Inc. | 4.59 Million USD | -13357.647% |
| Iterum Therapeutics plc | 32.66 Million USD | -1791.207% |